.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, clients along with metastatic gastrointestinal tumors who acquired biomarker-matched therapies based on spreading tumor DNA profiling revealed a higher clinical advantage than those acquiring incomparable therapy.